Active — Not RecruitingNot Applicable

Role of Sugammadex and Neostigmine for Recovery From Rocuronium

Egypt60 participantsStarted 2024-01-01

Plain-language summary

evaluation the reversal of neuromuscular blocking by sugammadex versus neostigmine through assessing the residual neuromuscular blocking effect by ultrasound imaging of expiratory muscle strength and diaphragmatic excursion.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with American Society of Anesthesiology (ASA) physical status classification I and II Exclusion Criteria: * 1\. American Society of Anesthesiology (ASA) physical status classification III-V 2. renal impairment 3. Significant liver disease (Child-Pugh B or C class) 4. History of chronic obstructive pulmonary disease 5. Known or suspected neuromuscular disease. 6. Cardiac arrhythmia or use of antiarrhythmic drugs.

What they're measuring

effect of sugammadex and neostigmine on reversal of rocuronium

Timeframe: 4 hours

Trial details

NCT IDNCT06432621

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-01

View on ClinicalTrials.gov More Anesthesia trials